Conmed reported that products within the gastro portfolio should generate between $90 million and $95 million in fiscal year 2025 (FY25). Within that total, distributing Gore’s stent produced $44.1 million in sales during the nine months ended 30 September 2025, according to the company’s latest Form 10-Q filing posted on the SEC website.
Despite withdrawing from a business expected to contribute roughly seven percent of annual revenue, Conmed reiterated its FY25 outlook. The firm continues to forecast approximately $1.37 billion in revenue and earnings of $4.48 to $4.53 per diluted share. Executives said the gastro departure will not materially affect top-line results in FY25.
Financial implications are projected to appear the following year. Conmed anticipates earnings dilution of $0.45 to $0.55 per share in 2026, reflecting lost sales, transition costs, and the absence of profit generated by the VIABIL stent.
Reaction on the New York Stock Exchange was immediate. Conmed shares fell almost ten percent on 5 December, closing at $40.07 after opening at $43.69. The drop left the company with a market capitalization of roughly $1.24 billion.
Chief Executive Officer Patrick J. Beyer stated that reallocating capital toward flagship surgical categories will position Conmed “for long-term success and continued leadership in surgical innovation.” The company did not disclose potential restructuring charges or workforce changes associated with the move.
Conmed has held exclusive rights to distribute Gore’s VIABIL stent in the United States and Canada since 2006. The device is used to treat malignant or benign biliary obstructions and competes with plastic and uncovered metal stents offered by multiple manufacturers. Olympus will inherit those distribution activities as part of its wider agreement with Gore; financial terms of that deal were not made public.
The remainder of Conmed’s gastroenterology catalogue includes retrieval nets, biopsy forceps, snares, injection needles and other disposable accessories used during diagnostic and therapeutic endoscopic procedures. These items will continue to be available until inventory is depleted or until unspecified transition arrangements are completed.
Portfolio optimization has been a recurring theme for Conmed in recent years. The company has expanded its presence in orthopedics through product launches in knotless soft-tissue fixation and has invested in minimally invasive surgical platforms, including powered instrumentation for arthroscopy and advanced energy systems for laparoscopic procedures. Management has indicated that capital freed from lower-growth categories will support additional research, development and possible acquisitions in those areas.
Industry observers note that exiting gastroenterology reduces Conmed’s exposure to pricing pressure in commodity-like endoscopy accessories, though it also removes a recurring cash flow stream. Competitors such as Boston Scientific and Olympus retain broad endoscopy portfolios, while companies including Intuitive Surgical and Stryker focus on higher-technology surgical segments—areas Conmed now appears keen to prioritize.
Conmed said it will provide updated guidance on transition costs, asset impairments or other one-time charges, if any, when it releases fourth-quarter and full-year 2025 results early next year. Until then, management plans to work with customers, distributors and regulatory agencies to ensure uninterrupted supply of affected gastroenterology products during the phase-out period.
Crédito da imagem: Mahmoud Suhail via Shutterstock.com
